-
[show abstract]
[hide abstract]
ABSTRACT: RATIONALE: Sanguinarine (SA) is currently used in veterinary medicine for animal husbandry as a natural component of feed additive Sangrovit. To date, SA metabolism in food-producing animals has not yet been reported. Therefore, the purpose of the present study was to investigate the metabolism of SA in pig liver microsomes and cytosol. METHODS: The SA incubations mixtures of microsomes and cytosol were processed by trichloroacetic acid (TCA) and acetonitrile. Then, the samples were analyzed using a sensitive and reliable method based on liquid chromatography combined with hybrid ion trap/time-of-flight mass spectrometry (LC-IT/TOFMS). The structural elucidations of these metabolites were performed by comparing the changes in the accurate molecular masses and product ions generated from precursor ions with those of the parent drug. RESULTS: Seven metabolites were identified in pig liver preparations. Dihydrosanguinarine (DHSA, m/z 334) was the main metabolite formed in liver microsomes and the only one in cytosol. One oxidative metabolite and two O-demethylenated metabolites of SA (m/z 320) were found in the TCA-treated microsomal samples. However, SA pseudobase and two additional O-demethylenated metabolites of DHSA (m/z 322) were found only in the acetonitrile-treated microsomal samples. CONCLUSIONS: It was demonstrated that different metabolites of SA were identified depending on the acidic or neural extraction conditions. A metabolic pathway of SA in pig was tentatively proposed based on these characterized metabolites and early reports. Copyright © 2013 John Wiley & Sons, Ltd.
Rapid Communications in Mass Spectrometry 05/2013; 27(9):979-984. · 2.79 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Angiopoietin-like protein 3 (Angptl3)-lipoprotein lipase (LPL) pathway may be a useful pharmacologic target for hyperlipidemia. The present study was conducted to test the effect of soluble fiber extracted from Undaria pinnatifida (UP), on hyperlipidemia in apolipoprotein E-deficient (ApoE(-/-)) mice. Forty mice were divided into four groups (n = 10): control group (C57BL/6J mice), ApoE(-/-) mice group, and two groups of ApoE(-/-) mice treated with UP fiber (5 or 10 % per day). UP soluble fiber treatment significantly decreased plasma and hepatic total cholesterol, triglycerides levels, plasma low-density lipoprotein cholesterol, and malondialdehyde concentrations and increased plasma high-density lipoprotein cholesterol level and downregulated protein expression of Angptl3 concomitantly with upregulated protein expression of LPL. In addition, T0901317 caused elevated expression of hepatic Angptl3 protein, and the effect of T0901317 was also abrogated by UP soluble fiber in C57BL/6J mice. The present results suggest that the UP soluble fiber regulates Angptl3-LPL pathway to lessen hyperlipidemia in mice.
Journal of physiology and biochemistry 04/2013; · 1.71 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Quinoxaline 1,4-di-N-oxides (QdNOs) derivatives (carbadox, olaquindox, mequindox, quinocetone, and cyadox) are the potent synthetic antimicrobial agents used in feed to improve feed efficiency and controlling dysentery in food-producing animals. Studies have demonstrated that the toxicity of QdNOs is closely associated with the production of their metabolism, especially with the production of their reduced metabolites. To the best of our knowledge, however, no one has systematically compiled the metabolism data of QdNOs. Therefore, the metabolism of QdNOs in animals is discussed in the review for the first time. These drugs undergo extensive metabolism prior to excretion. N-oxide group reduction is the major metabolic pathway of QdNOs. Moreover, the N1-oxide reduction and N4-oxide reduction of QdNOs by different reducing mechanisms are also described. Obvious differences in metabolic pathways for QdNOs are observed owing to the differences on the side chain of these drugs. Therefore, understanding the metabolic pathways of QdNOs in animals will provide the guides for further studies of metabolism and toxicology of these drugs.
Medicinal chemistry (Shāriqah (United Arab Emirates)) 03/2013; · 1.64 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Background: Inhibiting the action of proprotein convertase subtilisin/kexin type 9 (PCSK9) on the low-density lipoprotein receptor (LDLR) has emerged as a novel therapeutic target for hypercholesterolemia. Here we investigated the effect of berberine, natural plant extracts, on PCSK9-LDLR pathway in C57BL/6 mice with lipopolysaccharide (LPS) induced inflammation. Methods: Forty female mice were divided into four groups (n =10): control, LPS (5 mg/kg), LPS + berberine 10 (5 mg/kg LPS plus 10 mg/kg berberine), and LPS + berberine 30 (5 mg/kg LPS plus 30 mg/kg berberine). Changes in the levels of blood lipids [total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C)]; pro-inflammatory cytokines [interferon-γ (IFNγ), tumor necrosis factor α (TNFα), and interleukin-1α (IL-1α)], 8-isoprostane, hepatic expressions of PCSK9 and LDLR were determined. Results: Berberine pretreatment reduced the expression of hepatic PCSK9, decreased the plasma TC, TG, LDL-C, IFNγ, TNFα, IL-1α, and 8-isoprostane concentrations; increased HDL-C level and LDLR expression in mice. Conclusion: The present results suggest that berberine inhibits dyslipidemia in C57BL/6 mice with LPS induced inflammation through regulating PCSK9-LDLR pathway.
Pharmacological reports: PR 07/2012; 64(4):889-95. · 2.44 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Ketosis is a metabolic disorder closely associated with both lipid and carbohydrate metabolism. Recent studies show that angiopoietin-like protein 3 (ANGPTL3) contributes to the development of metabolic disorder. The objective of this study was to explore the inhibitory effect of 1,3,5,8-tetrahydroxyxanthone (Xan), a naturally occurring flavonoid compound, on ketosis and the mechanisms involved in this regulation. After 4weeks, Xan (10 or 30mg/kg, intragastrically) treatment decreased plasma total ketone bodies, malondialdehyde, 8-isoprostane, triglyceride, total cholesterol levels, and hepatic ANGPTL3 expression concomitantly with increased plasma glucose concentration and adipose lipoprotein lipase (LPL) expression in ketosis murine. The present results suggest that Xan regulates ANGPTL3-LPL pathway to lessen the ketosis in mice.
European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 02/2012; 46(1-2):26-31. · 2.61 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Recent studies show that osteopontin (OPN) and its receptor cluster of differentiation 44 (CD44) are two pro-inflammatory cytokines contributing to the development of atherosclerosis. The objective of this study was to explore the inhibitory effect of kaempferol, a naturally occurring flavonoid compound, on atherogenesis and the mechanisms involved. The experiments were performed in aorta and plasma from C57BL/6J control and apolipoprotein E-deficient (ApoE(-/-)) mice treated or not with kaempferol (50 or 100mg/kg, intragastrically) for 4 weeks. Kaempferol treatment decreased atherosclerotic lesion area, improved endothelium-dependent vasorelaxation, and increased the maximal relaxation value concomitantly with decrease in the half-maximum effective concentration, plasma OPN level, aortic OPN expression, and aortic CD44 expression in ApoE(-/-) mice. In addition, treatment with kaempferol also significantly decreased reactive oxygen species production in mice aorta. The present results suggest that kaempferol regulates OPN-CD44 pathway to inhibit the atherogenesis of ApoE(-/-) mice.
Toxicology and Applied Pharmacology 12/2011; 257(3):405-11. · 4.45 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Trimethoprim (TMP) and diaveridine (DVD) are used in combination with sulfonamides and sulfaquinoxlaine as an effective antibacterial agent and antiprotozoal agent, respectively, in humans and animals. To gain a better understanding of the metabolism of TMP and DVD in the food-producing animals, the metabolites incubated with liver microsomes of pigs were analyzed for the first time with high-performance liquid chromatography combined with hybrid ion trap/time-of-flight mass spectrometry. Seven TMP-related and six DVD-related metabolites were characterized based on the accurate MS² spectra and known structure of the parent drug, respectively. The metabolites of TMP were identified as two O-demethylation metabolites, a di-O-demethylation metabolite, two N-oxides metabolites, a hydroxylated metabolite on the methylene carbon and a hydroxylated metabolite on the methyl group. DVD was also biotransformed to two O-demethylation metabolites, a di-O-demethylation metabolite, an N-oxide metabolite, a hydroxylation metabolite on the methylene carbon and a hydroxylation metabolite followed by O-demethylation. The results indicate that the two compounds have similar biotransformation pathways in pigs. O-Demethylation was the major metabolic route of TMP and DVD in the pig liver microsomes. The proposed metabolic pathways of TMP and DVD in liver microsomes will provide a basis for further studies of the in vivo metabolism of the two drugs in food-producing animals.
Biomedical Chromatography 12/2011; 26(9):1101-8. · 1.97 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A new strategy using hybrid ion trap/time-of-flight mass spectrometry coupled with high-performance liquid chromatography and post-acquisition data mining techniques was developed and applied to the detection and characterization of degradation products of danofloxacin. The degradation products formed under different forced conditions were separated using an ODS-C18 column with gradient elution. Accurate full-scan MS data were acquired in the first run and processed with the combination of extracted ion chromatograms and LC-UV chromatograms. These processes were able to find accurate molecular masses of possible degradation products. Then, the accurate MS/MS data acquired through data-dependent analysis mode in another run facilitated the structural elucidations of degradation products. As a result, a total of 11 degradation products of danofloxacin were detected and characterized using the developed method. Overall, this analytical strategy enables the acquisition of accurate-mass LC/MS data, search of a variety of degradation products through the post-acquisition processes, and effective structural characterization based on elemental compositions of degradation product molecules and their product ions. The ability to measure degradation products via tandem mass spectrometry coupled with accurate mass measurement, all in only two experimental runs, is one of the most attractive features of this methodology. The results demonstrate that use of the LC/MS-IT-TOF approach appears to be rapid, efficient and reliable in structural characterization of drug degradation products.
Analytical and Bioanalytical Chemistry 03/2011; 399(7):2475-86. · 3.78 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Previous investigations have indicated that reduced erythrocyte deformability may be an important factor contributing to the development of atherosclerosis, and endogenous asymmetric dimethylarginine (ADMA) might be an important contributor to reduction of erythrocyte deformability in atherosclerosis. In this study, the effect of 3,4,5,6-tetrahydroxyxanthone (1), a kind of polyphenolic compound, on erythrocyte deformability in apolipoprotein E-deficient (apoE-/-) mice was evaluated. After treatment with compound 1 (10 or 20 mg/kg per day) for 4 weeks, erythrocyte deformability, antioxidant enzymes activity, erythrocyte dimethylarginine dimethylaminohydrolase (DDAH) activity, the plasma level of ADMA and malondialdehyde (MDA) level were determined. Treatment with compound 1 (10 or 20 mg/kg) increased erythrocyte deformability, antioxidant enzymes activity concomitantly, a decrease in the plasma levels of MDA and ADMA, and an increase in erythrocyte DDAH activity. The present result suggests that the beneficial effect of 1 on the erythrocyte deformability, besides inhibiting lipid peroxidation, may be related to reduction of ADMA concentration via an increase in DDAH activity.
Journal of Asian natural products research 07/2009; 11(7):643-51. · 0.61 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Previous investigations have shown that asymmetric dimethylarginine (ADMA) inhibits nitric oxide (NO) synthases (NOS) and that ADMA is a risk factor for endothelial dysfunction. The objective of this study was to investigate the protective effect of kaempferol, a naturally occurring flavonoid antioxidant agent, against endothelial damage and the mechanisms involved. The experiments were performed in aorta and plasma from C57BL/6J control and apolipoprotein E-deficient (ApoE(-/-)) mice treated or not with kaempferol (50 or 100mg/kg, intragastrically) for 4 weeks, and in human umbilical vein endothelial cells (HUVECs) pretreated or not with kaempferol (1, 3 or 10 microM) for 1h and exposed to lysophosphatidylcholine (LPC) (10 microg/mL) for 24h. Kaempferol treatment improved endothelium-dependent vasorelaxation, increased the maximal relaxation value, and decreased the half-maximum effective concentration concomitantly with an increase in nitric oxide plasma concentration, a decrease in ADMA and malondialdehyde (MDA) plasma concentrations, and increase in the expression of aortic endothelial NOS (eNOS) as well as dimethylarginine dimethylaminohydrolase II (DDAH II) in ApoE(-/-) mice. In addition, LPC caused a reduction in NO production, an increase in ADMA concentration concomitantly with a decreased expression of eNOS and DDAH II in HUVECs, and the effect of LPC was abolished by kaempferol. Treatment with kaempferol also significantly decreased reactive oxygen species production in mice aorta and in HUVECs. The present results suggest that the protective effect of kaempferol against endothelial damage may be associated with an improvement in NO production and a decrease in ADMA level.
European journal of pharmacology 07/2009; 616(1-3):213-22. · 2.59 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Previous investigations have shown that decreased expression of angiopoietin-like protein 3 (Angptl3) is protective against dyslipidemia in atherosclerosis. The present study was conducted to test the effect of 3,4,5,6-tetrahydroxyxanthone, a xanthone compound, on dyslipidemia in apolipoprotein E-deficient (ApoE-/-) mice. Forty mice were randomly divided into 4 groups (n = 10): control group (C57BL/6J mice), ApoE-/-mice group, and two groups of ApoE-/- mice treated with 3,4,5,6-tetrahydroxyxanthone (10 or 30 mg/kg per day). Eight weeks after treatment, lipid levels in the blood and liver, expression of hepatic Angptl3, and adipose tissue lipoprotein lipase (LPL) were determined. Treatment with 3,4,5,6-tetrahydroxyxanthone (10 or 30 mg/kg) significantly decreased plasma and hepatic total cholesterol and triglyceride concentrations, increased plasma high-density lipoprotein cholesterol, and significantly downregulated expression of Angptl3 mRNA and protein concomitantly with upregulated expression of LPL mRNA. In addition, T0901317 (a liver X receptor ligand) caused elevated expression of hepatic Angptl3 mRNA and protein, and the effect of T0901317 was also abrogated by 3,4,5,6-tetrahydroxyxanthone in vivo and in vitro. The present results suggest that the beneficial effect of 3,4,5,6-tetrahydroxyxanthone on dyslipidemia may be related to reduced expression of Angptl3.
Canadian Journal of Physiology and Pharmacology 12/2008; 86(12):815-26. · 1.95 Impact Factor
